There is good news for arthritis sufferers as the National Institute for Clinical Excellence (NICE) has opted to rethink its decision to limit access to anti-TNF medications.
The drugs in question are infliximab, etanercept and adminulab, which inhibit TNF attacks and can enable sufferers to live an active life.
Their cost-effectiveness was questioned by NICE last year, imposing limitations on patient's access to the medicines, prompting a backlash from various groups.
A spokeswoman from NICE said: "While individual appeals were dismissed, the appeal panel decided that the appraisal committee needed to take another look at the use of a second anti-TNF treatment where there had been no response to a first anti-TNF treatment."
Some 400,000 Britons suffer with rheumatoid arthritis, a disease causing the immune system to fail in protecting the body.
Neil Betteridge, chief executive of Arthritis Care, said: "People eligible to receive anti-TNF treatment are, by definition, people with severe rheumatoid arthritis, a disease which, if left untreated, leads to serious disability, often at a young age.
"If not properly treated, those with the most severe form die on average within five years."
He continued: "We're talking about people for whom these drugs are the last hope, for whom there is nothing else beyond palliative care."